Published on 23/12/2025

Periodic Safety Update Reporting for Veterinary Medicines

Periodic Safety Update Reports (PSURs) are a crucial component of the pharmacovigilance framework for veterinary medicines. This step-by-step guide is tailored for professionals involved in veterinary regulatory affairs, quality assurance (QA), regulatory affairs (RA), and pharmacovigilance. Emphasizing compliance with regulatory bodies in the US (FDA), UK (MHRA), and EU (EMA), this article provides comprehensive insights into the creation of compliant PSURs for veterinary medicines.

Understanding Periodic Safety Update Reports (PSURs)

PSURs are standardized documents that summarize the safety profile of a veterinary medicinal product. They are updated periodically to reflect the current understanding of a product’s risk-benefit profile. In the context of veterinary pharmacovigilance, PSURs are critical for evaluating the continued safety and efficacy of veterinary medicines after market authorizations.

Regulatory Framework

The regulatory framework governing PSURs varies across jurisdictions, but there are commonalities that professionals must adhere to. In the US, the FDA’s Center for Veterinary Medicine (CVM) oversees regulations relevant to veterinary medicines. In the EU, the European Medicines Agency (EMA) provides oversight, aligned with the veterinary medicinal product regulation (EU) 2019/6. In the UK, the Medicines and Healthcare products Regulatory Agency (MHRA) provides guidance aligned with its own regulations. Understanding these frameworks is essential for effective veterinary pharmacovigilance consulting services.

Key Components of PSURs

• Introduction: General information about the medicinal product, including details of the active substance, product formulation, and target species.
• Safety Information: Summarize the safety data collected since the last PSUR, including adverse reactions reported both in clinical trials and post-marketing.
• Risk Assessment: Evaluate any potential new risks identified and assess their implications on the benefit-risk ratio of the product.
• Conclusions and Actions: Provide recommendations based on the findings, including any necessary changes to product information or risk management measures.

Step 1: Data Collection

The foundation of any effective PSUR is robust data collection. It is essential to gather data from multiple sources, including:

• Clinical Trials: Data from pre- and post-market studies, which can provide insights into adverse events and treatment outcomes.
• Post-Marketing Surveillance: Reports from veterinarians and pet owners, including spontaneous reports of adverse drug reactions.
• Literature Review: Published research that may provide additional context or findings related to the product.

For optimal data integrity, ensure that all data collected is compliant with veterinary pharmacovigilance requirements and regulations. Utilizing standardized reporting forms can streamline this process.

Step 2: Assessing Safety Data

Once data is collected, it must be carefully assessed to identify trends or signals that may indicate new safety concerns. The assessment should involve:

• Signal Detection: Analyze the frequency and severity of reported adverse events compared to the expected rates based on historical data and literature.
• Benefit-Risk Evaluation: Evaluate whether the benefits of the veterinary medicine continue to outweigh its risks based on the latest safety data.

Decisions made during this stage will directly influence the development of the product’s safety profile and future recommendations, making it pivotal in the PSUR preparation process.

Step 3: Writing the PSUR

The next step involves drafting the PSUR document itself. This process can be broken down into sections, each requiring careful consideration of the information gathered and analyses conducted.

Structuring the Report

Follow a structured format that aligns with regulatory expectations. The report should include:

• Executive Summary: A concise summary of the key findings and recommendations.
• Product Overview: Details about the product including approval date, indications, and dosing information.
• Safety Data Overview: Present a comprehensive review of new safety information, including a discussion of any new risks.
• Conclusions and Future Plans: Discuss how the safety data will inform future risk management strategies or labeling changes.

Step 4: Regulatory Submission

After preparing the PSUR, the next critical phase is making the appropriate regulatory submission to the relevant authorities.

Submission Procedures

Each region has distinct regulations and submission procedures:

• For the FDA (CVM): PSURs may be submitted via the FDA’s electronic submission gateway. Ensure that proper formats are adhered to as per FDA guidelines.
• For EMA and MHRA: Follow the requirements outlined in the applicable regulations including submission formats and timings. Regular submissions may be conducted through the EudraVigilance system for EMA, while MHRA follows its own notification protocols.

Before the submission, verify that the PSUR meets all content and formatting requirements set by the respective authority to prevent delays or rejections.

Step 5: Follow-Up Actions and Market Surveillance

Upon submitting the PSUR, ongoing monitoring of the product in the market remains crucial. Follow-up actions may include:

• Implementation of Recommendations: Adapting product labels, communicating safety information to stakeholders, or conducting further investigations as necessary.
• Conducting Additional Studies: If new safety concerns arise or significant signals are detected, it may be necessary to implement further studies to gather more data.

Beyond the regulatory submission, maintaining an active post-market surveillance plan can enhance the product’s safety profile and ensure ongoing compliance with pharmacovigilance obligations. This includes staying vigilant and responsive to new information and emerging trends.

Conclusion

Creating and submitting Periodic Safety Update Reports for veterinary medicines is a multifaceted process that demands rigorous adherence to established regulatory frameworks in regions such as the US, UK, and EU. By understanding the key components and following a structured approach, veterinary regulatory professionals can ensure compliance and contribute to the effective monitoring of veterinary medicinal products. The integration of veterinary pharmacovigilance consulting services can provide invaluable support in this process, further ensuring the safety and well-being of both animals and human users alike.

Additional Resources

For further reading and references related to veterinary pharmacovigilance and PSURs, consult the following resources:

• FDA’s Animal Veterinary website for pertinent guidelines and updates.
• EMA’s Official Guidelines to understand the requirements under EU regulations.
• WHO Guidelines on Safety Monitoring to enhance your insight into global standards.